Evidence map›Paper›PMID 32824003›Full record

ArticleCancers2020

A 3D Heterotypic Breast Cancer Model Demonstrates a Role for Mesenchymal Stem Cells in Driving a Proliferative and Invasive Phenotype.

Amarnath Pal, Jennifer C Ashworth, Pamela Collier, Catherine Probert, Sal Jones, Eduardo Pernaut Leza, Marian L Meakin, Alison A Ritchie, David Onion, Philip A Clarke and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Unlocking the Therapeutic Potential of Integrin-Linked Kinase Inhibitors in Bioengineered 3D Breast Tumor Stroma Models.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. The role of mesenchymal cells in cholangiocarcinoma.Disease models & mechanisms · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Amarnath PalEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Jennifer C AshworthEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.ORCID 0000-0003-4189-8876
Pamela CollierEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Catherine ProbertEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Sal JonesEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Eduardo Pernaut LezaEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Marian L MeakinEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Alison A RitchieEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
David OnionUniversity of Nottingham Flow Cytometry Facility, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.ORCID 0000-0002-4522-2307
Philip A ClarkeEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Cinzia AllegrucciSVMS, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0001-8517-2423
Anna M GrabowskaEx Vivo Cancer Pharmacology Centre, Division of Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.ORCID 0000-0003-1507-921X
University of Nottingham · GB

Funding

Breast Cancer Now 2016MaySP763Cancer Research UK 22897National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001861/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/N001583/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/P002285/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T001259/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T001267/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T2T0219
6 · The paper itself

Abstract

Previous indirect 2D co-culture studies have demonstrated that mesenchymal stem cells (MSCs) promote breast cancer (BC) progression through secretion of paracrine factors including growth factors, cytokines and chemokines. In order to investigate this aspect of the tumour microenvironment in a more relevant 3D co-culture model, spheroids incorporating breast cancer cells (BCCs), both cell lines and primary BCCs expanded as patient-derived xenografts, and MSCs were established. MSCs in co-cultures were shown to enhance proliferation of estrogen receptor (ER)/progesterone receptor (PR)-positive BCCs. In addition, co-culture resulted in downregulation of E-cadherin in parallel with upregulation of the epithelial-mesenchymal transition (EMT)-relation transcription factor, SNAIL. Cytoplasmic relocalization of ski-related novel protein N (SnON), a negative regulator of transforming growth factor-beta (TGF-β) signalling, and of β-catenin, involved in a number of pathways including Wnt signalling, was also observed in BCCs in co-cultures in contrast to monocultures. In addition, the β-catenin inhibitor, 3-[[(4-methylphenyl)sulfonyl]amino]-benzoic acid methyl ester (MSAB), mediated reduced growth and invasion in the co-cultures. This study highlights the potential role for SnON as a biomarker for BC invasiveness, and the importance of interactions between TGF-β and Wnt signalling, involving SnON. Such pathways may contribute towards identifying possible targets for therapeutic intervention in BC patients.

Indexed as

epithelial-mesenchymal transition (EMT)mesenchymal stem cells (MSCs)ski-related novel protein N (SnON)spheroid co-culture modelTGF-β signallingtumour microenvironment (TME)tumour stromaWnt signalling

Identifiers

PMID32824003
PMCPMC7465555
OpenAlexW3049119666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.